Skip Navigation LinksHome > August 2014 - Volume 9 - Issue 8 > NCCTG N0821 (Alliance): A Phase II First-Line Study of Pemet...
Journal of Thoracic Oncology:
doi: 10.1097/JTO.0000000000000217
Original Articles

NCCTG N0821 (Alliance): A Phase II First-Line Study of Pemetrexed, Carboplatin, and Bevacizumab in Elderly Patients with Advanced Nonsquamous Non–Small-Cell Lung Cancer With Good Performance Status

Dy, Grace K. MD*; Molina, Julian R. MD, PhD; Qi, Yingwei PhD; Ansari, Rafat MD; Thomas, Sachdev MD§; Ross, Helen J. MD; Soori, Gamini MD; Anderson, Daniel MD#; Aubry, Marie Christine MD; Meyers, Jeffrey BS; Adjei, Araba A. PhD*; Mandrekar, Sumithra PhD; Adjei, Alex A. MD, PhD*

Collapse Box

Abstract

Background:

We hypothesized that the combination of bevacizumab, carboplatin, and pemetrexed will be an effective first-line regimen in fit, elderly patients with nonsquamous non–small-cell lung cancer.

Methods:

Treatment-naïve, stage IIIB/IV nonsquamous non–small-cell lung cancer patients more than 70 years old with good performance status (Eastern Cooperative Oncology Group performance status 0–1) and adequate organ function were eligible. Carboplatin area under the curve 6, pemetrexed 500 mg/m2, and bevacizumab 15 mg/kg were administered on day 1 of each 21-day cycle (up to six cycles) followed by maintenance pemetrexed and bevacizumab. The primary end point of 6-month progression-free survival rate of at least 70% was assessed using a one-stage binomial design. Quality of life (QOL) questionnaires were administered. Polymorphisms in genes encoding relevant proteins (drug targets, transport, and metabolism proteins) were correlated with treatment outcome.

Results:

Fifty-seven eligible patients were enrolled. Median age was 74.5 years. Median treatment cycles received was 6. The most common grade 3 or higher non-hematologic adverse events were fatigue (26%) and hypertension (11%); 16% had grade 4 neutropenia and 6.5% had grade 4 thrombocytopenia. Three patients experienced grade 3/4 hemorrhagic events (one pulmonary, two gastrointestinal). Primary end point of PFS6 was 60% (95% confidence interval [CI]: 45.9–73%). Median PFS was 7.0 months (95% CI: 5.9–10.1), median overall survival was 13.7 months (95% CI: 9.4–16.8). Polymorphic KDR and VEGFA variants correlated with survival and toxicity, respectively. There was no significant change in overall QOL scores over time.

Conclusion:

This regimen is feasible and did not decrease the QOL in this study population. However, it did not meet the primary efficacy end point.

Copyright © 2014 by the International Association for the Study of Lung Cancer

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Other Ways to Connect

Twitter
twitter.com/JTOonline

 



Visit JTO.org on your smartphone. Scan this code (QR reader app required) with your phone and be taken directly to the site.

 For additional oncology content, visit LWW Oncology Journals on Facebook.